NICE accepts aripiprazole for bipolar disorder in adolescents

NICE has approved the use of aripiprazole (Abilify) in adolescents with bipolar I disorder for treating moderate to severe manic episodes.

Abilify is also approved by NICE for treating schizophrenia in patients aged 15 to 17 years when risperidone is unsuitable.
Abilify is also approved by NICE for treating schizophrenia in patients aged 15 to 17 years when risperidone is unsuitable.

The atypical antipsychotic aripiprazole (Abilify) is recommended by NICE for use within its licensed indication in adolescents aged 13 years and over for up to 12 weeks.

It is also approved for use on the NHS by NICE for treating schizoprenia in patients aged 15–17 years when risperidone is contraindicated, not tolerated or does not provide adequate symptom control.

View Abilify drug record

NICE guidance on aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...